Page last updated: 2024-10-31

midodrine and Hepatitis C

midodrine has been researched along with Hepatitis C in 2 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Research Excerpts

ExcerptRelevanceReference
" Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure."6.69Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999)
" Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure."2.69Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Olivera-Martinez, M1
Martinez, MO1
Sayles, H1
Vivekanandan, R1
D' Souza, S1
Florescu, MC1
Angeli, P1
Volpin, R1
Gerunda, G1
Craighero, R1
Roner, P1
Merenda, R1
Amodio, P1
Sticca, A1
Caregaro, L1
Maffei-Faccioli, A1
Gatta, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355]Phase 429 participants (Actual)Interventional2003-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Development of Post-paracentesis Circulatory Dysfunction (PCD)

Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis

Interventionparticipants (Number)
Albumin (Control Group)2
Vasoconstrictor (Treatment Group)2

Time to Recurrence of Ascites.

Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days

Interventiondays (Median)
Albumin (Control Group)10
Vasoconstrictor (Treatment Group)8

Trials

1 trial available for midodrine and Hepatitis C

ArticleYear
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Hepatology (Baltimore, Md.), 1999, Volume: 29, Issue:6

    Topics: Aldosterone; Ascites; Blood Pressure; Diuresis; Electrolytes; Gastrointestinal Agents; Glomerular Fi

1999

Other Studies

1 other study available for midodrine and Hepatitis C

ArticleYear
Hepatorenal syndrome: are we missing some prognostic factors?
    Digestive diseases and sciences, 2012, Volume: 57, Issue:1

    Topics: Albumins; Alcoholism; Autoimmune Diseases; Creatinine; End Stage Liver Disease; Female; Hepatitis C;

2012